Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02516410
Registration number
NCT02516410
Ethics application status
Date submitted
28/07/2015
Date registered
5/08/2015
Date last updated
12/06/2018
Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)
Query!
Secondary ID [1]
0
0
2014-004787-37
Query!
Secondary ID [2]
0
0
VX14-661-107
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Cystic fibrosis
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - VX-661 plus ivacaftor combination
Treatment: Drugs - Ivacaftor
Treatment: Drugs - Placebo (matched to VX-661 plus ivacaftor combination)
Treatment: Drugs - Placebo (matched to ivacaftor)
Experimental: VX-661/IVA - VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
Placebo Comparator: Placebo - Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
Treatment: Drugs: VX-661 plus ivacaftor combination
Treatment: Drugs: Ivacaftor
Treatment: Drugs: Placebo (matched to VX-661 plus ivacaftor combination)
Treatment: Drugs: Placebo (matched to ivacaftor)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12
Query!
Assessment method [1]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
Query!
Timepoint [1]
0
0
Baseline, Through Week 12
Query!
Secondary outcome [1]
0
0
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12
Query!
Assessment method [1]
0
0
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Query!
Timepoint [1]
0
0
Baseline, Through Week 12
Query!
Secondary outcome [2]
0
0
Number of Pulmonary Exacerbation Events
Query!
Assessment method [2]
0
0
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported.
Query!
Timepoint [2]
0
0
Baseline through Week 12
Query!
Secondary outcome [3]
0
0
Number of Pulmonary Exacerbation Events Per Year
Query!
Assessment method [3]
0
0
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Total number of days on study is equal to the Week 12 date or the last dose date (whichever occurs last) minus first dose date plus 1. The total number of years (48 weeks) on study is equal to the total number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.
Query!
Timepoint [3]
0
0
Baseline through Week 12
Query!
Secondary outcome [4]
0
0
Absolute Change From Baseline in Body Mass Index (BMI) at Week 12
Query!
Assessment method [4]
0
0
BMI was defined as weight in kilogram (kg) divided by height*height in square meter (m^2).
Query!
Timepoint [4]
0
0
Baseline, Week 12
Query!
Secondary outcome [5]
0
0
Relative Change From Baseline in Percent Predicted FEV1 Through Week 12
Query!
Assessment method [5]
0
0
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.
Query!
Timepoint [5]
0
0
Baseline, Through Week 12
Query!
Secondary outcome [6]
0
0
Absolute Change From Baseline in Sweat Chloride Through Week 12
Query!
Assessment method [6]
0
0
Sweat samples were collected using an approved collection device.
Query!
Timepoint [6]
0
0
Baseline, Through Week 12
Query!
Secondary outcome [7]
0
0
Number of Participants With at Least One Pulmonary Exacerbation Through Week 12
Query!
Assessment method [7]
0
0
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.
Query!
Timepoint [7]
0
0
Baseline through Week 12
Query!
Secondary outcome [8]
0
0
Absolute Change From Baseline in BMI Z-score at Week 12 (in Participants Less Than [<] 20 Years Old at the Time of Screening)
Query!
Assessment method [8]
0
0
Z-score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is, with range from infinity to +infinity; where 0: same mean, >0: a greater mean, and <0: a lesser mean than the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age Z-score (BMI z-score). BMI-for-age z-score was calculated by using centers for disease control and prevention (CDC) growth charts for the paediatric population.
Query!
Timepoint [8]
0
0
Baseline, Week 12
Query!
Secondary outcome [9]
0
0
Absolute Change From Baseline in Body Weight at Week 12
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Baseline, Week 12
Query!
Secondary outcome [10]
0
0
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [10]
0
0
AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or newly developed at or after initial dosing of study drug to Week 16 was considered treatment-emergent.
Query!
Timepoint [10]
0
0
Baseline up to Week 16
Query!
Secondary outcome [11]
0
0
Trough Plasma Concentrations (Ctrough) of VX-661, VX-661 Metabolite (M1 VX-661), Ivacaftor (IVA) and IVA Metabolite (M1-IVA)
Query!
Assessment method [11]
0
0
This outcome was not planned to be assessed in Placebo arm.
Query!
Timepoint [11]
0
0
Pre-morning dose on Week 2, Week 4, Week 8 and Week 12
Query!
Eligibility
Key inclusion criteria
- Confirmed diagnosis of CF defined as a sweat chloride value greater than or equal to
(>=)60 millimole per liter (mmol/L) by quantitative pilocarpine iontophoresis.
- Heterozygous for the F508del-CFTR mutation and with a second CFTR mutation that is not
likely to respond to VX-661 and/or ivacaftor therapy, genotype to be confirmed via
assessment at the Screening Visit.
- Forced Expiratory Volume in 1 Second (FEV1) >=40 percent (%) and less than or equal to
(<=)90% of predicted normal for age, sex, and height at Screening Visit.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of any comorbidity that, in the opinion of the investigator, might confound
the results of the study or pose an additional risk in administering study drug to the
participant.
- An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
therapy (including antibiotics) for pulmonary disease within 28 days before Day 1
(first dose of study drug).
- History of solid organ or hematological transplantation.
- Ongoing or prior participation in an investigational drug study or use of commercially
available CFTR modulator within 30 days of screening.
- Pregnant or nursing females.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
7/06/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
168
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
- Brisban
Query!
Recruitment hospital [2]
0
0
- Chermside
Query!
Recruitment hospital [3]
0
0
- Herston
Query!
Recruitment hospital [4]
0
0
- Innsbruck
Query!
Recruitment hospital [5]
0
0
- Westmead
Query!
Recruitment postcode(s) [1]
0
0
- Brisban
Query!
Recruitment postcode(s) [2]
0
0
- Chermside
Query!
Recruitment postcode(s) [3]
0
0
- Herston
Query!
Recruitment postcode(s) [4]
0
0
- Innsbruck
Query!
Recruitment postcode(s) [5]
0
0
- Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nebraska
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Tennessee
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Virginia
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Austria
Query!
State/province [19]
0
0
Graz
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Innsbruck
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Salzburg
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
British Columbia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Montreal
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Bron Cedex
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Montpellier Cedex 5
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Paris Cedex 14
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Paris Cedex 19
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris
Query!
Country [29]
0
0
Israel
Query!
State/province [29]
0
0
Haifa
Query!
Country [30]
0
0
Israel
Query!
State/province [30]
0
0
Hashomer
Query!
Country [31]
0
0
Israel
Query!
State/province [31]
0
0
Jerusalem
Query!
Country [32]
0
0
Israel
Query!
State/province [32]
0
0
Petah Tikva
Query!
Country [33]
0
0
Spain
Query!
State/province [33]
0
0
Barcelona
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Vertex Pharmaceuticals Incorporated
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Study to evaluate the efficacy of VX-661 in combination with ivacaftor (IVA, VX-770) through
Week 12 in participants with cystic fibrosis (CF) who are heterozygous for the F508del
mutation on the CF transmembrane conductance regulator (CFTR) gene and with a second CFTR
mutation that is not likely to respond to VX-661 and/or IVA therapy (F508del/not responsive
[NR]).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02516410
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02516410
Download to PDF